29 reports

The two major HIV subtypes are HIV-## and HIV-##.

  • Antiviral
  • HIV Antiviral
  • Therapy
  • World
  • Market Shares
  • MERCK & CO.
  • ABBVIE INC.

PRODUCT CATEGORIES: ANTIVIRALS.

  • HIV Antiviral
  • North America
  • World
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company

ONE UNIT REFERS TO ONE PROBE.

  • Endoscopic Device
  • HIV Antiviral
  • East Asia
  • South Korea
  • Market Size

Gilead and GlaxoSmithKline Plc. ##.

  • HIV Antiviral
  • World
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • TREATMENT ACCESS
  • 6.6 CHINA

ANTIVIRAL ACTIVITY OF APRICITABINE IN TREATMENT-EXPERIENCED HIV-##-INFECTED PATIENTS WITH M##V WHO ARE FAILING COMBINATION THERAPY.

  • HIV Antiviral
  • East Asia
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare Ltd.
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

Antiviral therapy suppresses the replication of HIV infection in the body.

  • HIV Antiviral
  • China
  • Co. Shanghai Boeringer Ingelheim Pharmaceutical Co., Ltd.
  • Ltd. Beijing Sanjiu Wandong Pharmaceutical Co., Ltd.
  • UNAIDS

ONE UNIT REFERS TO ONE PROBE.

  • Endoscopic Device
  • HIV Antiviral
  • Northern Europe
  • United Kingdom
  • Market Size
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

ANTIVIRAL THERAPY SUPPRESSES THE REPLICATION OF HIV INFECTION IN THE BODY.

  • HIV Antiviral
  • China
  • Demand
  • Market Size
  • Supply

The company has also signed a deal worth $## billion with Moderna for its messenger RNA therapeutics platform in developing new antiviral vaccines and passive immunity therapies.

  • HIV Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • (EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE) + MARAVIROC SR - DRUG PROFILE
  • AG-1105 - DRUG PROFILE

Subjects were followed for a total of ## days for safety and antiviral effects.

  • HIV Antiviral
  • Medical Biotechnology
  • United States
  • World
  • CytoDyn Inc.
  • (EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE) + MARAVIROC SR - DRUG PROFILE
  • AG-1105 - DRUG PROFILE

Subjects were followed for a total of ## days for safety and antiviral effects.

  • Breast Cancer
  • HIV AIDS
  • HIV Antiviral
  • Therapy
  • CytoDyn Inc.
  • ONE OF THE PARTIES PURSUANT TO THE TERMS THEREOF.
  • GSK-214096 - DRUG PROFILE

SUBJECTS WERE FOLLOWED FOR A TOTAL OF ## DAYS FOR SAFETY AND ANTIVIRAL EFFECTS.

  • HIV Antiviral
  • Pharmaceutical
  • United States
  • Product Initiative
  • CytoDyn Inc.
  • Sobera Capital Acquires Equity Holdings in 12 Pharma Companies

One unit refers to one dura substitute.

  • Endoscopic Device
  • Health Services
  • Germany
  • Company
  • Market Segment

It has shown potent antiviral activity in seven clinical trials with HIV patients infected with the R## strain of HIV, which accounts for approximately ##% of HIV infected patients and up to ##% of those newly diagnosed.

  • HIV Antiviral
  • Medical Biotechnology
  • United States
  • Company
  • CytoDyn Inc.
  • SOBERA CAPITAL ACQUIRES EQUITY HOLDINGS IN 12 PHARMA COMPANIES

One unit refers to one dura substitute.

  • Endoscopic Device
  • United States
  • Company
  • Company Financials
  • Stryker Corporation
  • Sobera Capital Acquires Equity Holdings in 12 Pharma Companies

ONE UNIT REFERS TO ONE CLIP.

  • Endoscopic Device
  • HIV Antiviral
  • Hospital
  • Germany
  • Western Europe

The prominent features of this report are - ##.

  • HIV Antiviral
  • Lymphoma
  • Medical Biotechnology
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • HIV AIDS
  • HIV Antiviral
  • Immunotherapy
  • Lymphoma
  • F. Hoffmann-La Roche Ltd.

The primary endpoint evaluated antiviral activity and safety through ## weeks of maintenance treatment.

  • Healthcare
  • HIV AIDS
  • HIV Antiviral
  • United States
  • ViiV Healthcare Ltd.

ONE UNIT REFERS TO ONE PROBE.

  • Endoscopic Device
  • HIV Antiviral
  • Hospital
  • Germany
  • Western Europe

It inhibits HIV-## replication by non-competitive inhibition of HIV-## reverse transcriptase (RT).

  • HIV Antiviral
  • Laboratory
  • India
  • Supply
  • Mylan Inc.
  • Sobera Capital Acquires Equity Holdings in 12 Pharma Companies

One unit refers to one dura substitute.

  • Endoscopic Device
  • United Kingdom
  • Company
  • Market Segment
  • Medtronic, Inc.

It inhibits HIV-## replication by non-competitive inhibition of HIV-## reverse transcriptase (RT).

  • HIV Antiviral
  • Pharmaceutical
  • Ireland
  • Deals & Alliance
  • Janssen Biotech, Inc.

The company offers products such as insti HIV-##/ HIV-## antibody test and insti HIV-##/ HIV-## test controls.

  • Clinical Trial
  • Hepatitis
  • Hepatitis Testing
  • HIV Antiviral
  • Merck & Co., Inc.
  • HIV 1 Integrase (EC 2.7.7.) - Featured News & Press Releases

The primary endpoint evaluated antiviral activity and safety through ## weeks of maintenance treatment.

  • HIV AIDS
  • HIV Antiviral
  • United States
  • Product Initiative
  • ViiV Healthcare Ltd.

GlobalData Viriom Inc reported one pharmaceuticals & healthcare deal in YTD 2017.

  • HIV Antiviral
  • Pharmaceutical
  • United States
  • Deals & Alliance
  • Viriom

MYRCLUDEX HAS SHOWN AN EXCELLENT SAFETY PROFILE AND ANTIVIRAL EFFICACY IN SEVERAL CLINICAL TRIALS.

  • Anesthesia Equipment
  • Endoscopic Device
  • HIV Antiviral
  • Medical Device
  • Market Size
  • SOBERA CAPITAL ACQUIRES EQUITY HOLDINGS IN 12 PHARMA COMPANIES

One unit refers to one clip.

  • Endoscopic Device
  • HIV Antiviral
  • Neurological Disorder
  • Neurology
  • AorTech International plc
  • BUSINESS SEGMENTS

IT OFFERS ANTIVIRAL PRODUCTS FOR CARDIOVASCULAR AND RESPIRATORY DISEASES.

  • HIV AIDS
  • HIV Antiviral
  • Pharmaceutical
  • Company
  • Gilead Sciences, Inc.